Australia continues to attract significant investment from US investors, with the total figure of US investment into Australian life science companies totaling US1.43 billion and a strong growth trend over the five-year period, between 2018-2022.
An analysis of investment data by AusBiotech shows 100 deals between US-based investors and Australian-headquartered life sciences companies over the analysis period.
Fourteen deals totaling US$139.058 million were reported in 2018, 21 deals totaling US$229.269 million in 2019, 15 deals totaling US$125.619 million in 2020, 26 deals totaling US$294.75 million in 2021, and 24 deals totaling US$642.341 million in 2022.
The data includes both private and ASX-listed companies across the following subsectors: biotech, therapeutics, drug discovery, and medtech/medical devices; digital health; medical imaging and monitoring/sensors; surgical, dental and other medical devices; and agribiotech companies, including bio-based products, medicines for animal health, microbial technology, feed supplements to reduce methane emissions, and technologies.
Read more:
コメント